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Abstract
Cardiopulmonary exercise testing (CPET) is viewed by many as the gold standard for assessing exercise capacity in CF, being
recommended on an annual basis. However, not all patients undergo CPET for varying reasons. This service evaluation retrospectively
reviewed data from179 (92male) patients in a single CF centre in theUK to identify such reasons. A total of 75/179 patients underwent
CPET,whilst 104/179 did not. Of these 104, 41 patientswere≤ 11 years of age. Of the remaining 63 patients, 26 did not undergoCPET
for clinical reasons including needing IVantibiotics, musculoskeletal issues and obesity. Seventeen refused to undergo CPET because
of reasons such as an unwillingness to travel and dislike of CPET. Twenty did not undergo CPET for miscellaneous reasons including
difficulty contacting patients. Individuals with FEV1 < 40%predicted were 85.7% less likely to undertake a CPET than individuals with
FEV1 ≥ 70%predicted. Understanding these challenges will assist clinical teamswith future implementation of CPET into routine care, by
identifying areas for improvement and establishing strategies for enhancing future provision of the test.
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Introduction
A high level of aerobic fitness is beneficial to individuals with
cystic fibrosis (CF), with an increased level of fitness being
associated with a lower risk of mortality [1]. Given the impor-
tance of identifying and monitoring aerobic fitness, exercise
testing is recommended to take place annually [2].
Cardiopulmonary exercise testing (CPET) is acknowledged
as the ‘gold standard’methodology in CF [3], with this service
having been successfully implemented in some CF centres in
the United Kingdom (UK) [4].
Despite recommendations, many CF centres within the
National Health Service (NHS) of the UK do not perform
annual CPETs, instead using alternative ‘field’-based exercise
tests [5], such as the modified shuttle walk test (MSWT) and
six-minute walk test (6MWT). This preference is driven in
part by equipment availability [6].Within CF centres that offer
CPET as part of standard care, not all patients will perform
CPET, for reasons yet to be fully characterised.
To further develop services and facilitate implementation
of CPET nationally in CF centres, identification of challenges
faced by staff and patients is warranted. This service evalua-
tion goes some way towards this by providing reasoning as to
why some patients do not perform CPET in a combined (adult
and paediatric) CF centre in the UK.
Methods
Annual review data from a single calendar year (2017) for all
179 (92 male) patients with CF under the care of the Royal
Devon and Exeter NHS Foundation Trust Hospital CF service
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was retrospectively reviewed and analysed. As this service
evaluation (a) used anonymised data and (b) results could
not be generalised beyond the CF centre in question, an ethics
application was not required as per NHS Health Research
Authority guidelines.
Patient data at the time of annual review was collated to
provide profiles of individuals who did/did not undertake a
CPET, with characteristics provided in Table 1. Whilst a small
number of patients will undertake more than one exercise test
in a calendar year (e.g. evaluation of therapeutic regimens,
research studies), this does not happen for every patient.
Therefore, data presented herein is solely related to tests at
annual review as this is a timewhereby all patients are request-
ed to perform a CPET if possible.
Age at annual review was calculated and decimalised to the
nearest 0.1 years. To characterise sex, patients were assigned to
‘male’ and ‘female’ groups, based upon biological characteristics
at birth. Body mass index (BMI) was split into categories of
underweight (< 18.5), normal (18.5–24.9), overweight (25.0–
29.9) and obese (≥ 30) [7]. Forced expiratory volume in one
second (FEV1) was expressed as a percentage of predicted from
GLI equations [8], and split into categories of ‘mild’ (≥ 70%),
‘moderate’ (40 < 70%) and ‘severe’ lung disease (< 40%).
Reasons why patients did not undergo CPETwere identified
from physiotherapy annual reviews, and split into three broad
categories: clinical, refusal and miscellaneous. Clinical and mis-
cellaneous reasons were categorised by clinical staff, and refusals
were stated by the patients themselves. Where patients did not
undergo CPET (for any reason), participation in alternative field
tests of MSWT [9] and 6MWT [10] was also assessed.
All statistical analyses were performed using IBM SPSS
v.24 (IBM, Armonk, NY, USA). Chi-squared tests identified
associations between uptake of CPETand sex, BMI and FEV1
categories. Logistic regression identified whether sex or cate-
gories of BMI or FEV1 predicted likelihood of patients
performing CPET, in those eligible for the test. Significance
was set at p < 0.05.
Results
Annual review data of all 179 patients was successfully
reviewed, with patient characteristics provided in
Table 1. Within this sample, 138 patients were eligible
for CPET. Of the 75 performing CPET, 13/75 did not use
on-line gas analysis (62/75 did) due to microbiological
contraindications (e.g. non-tuberculous mycobacteria,
Burkholderia cepacia). Patient eligibility and uptake of
CPET is displayed in Fig. 1.
Of all 179 patients, 41 were deemed too young (all were
aged ≤ 11 years) for CPET, and therefore 21 performed a
MSWT instead, completing a mean distance (± standard de-
viation) of 839 ± 199 m (range 350–1080 m). Of the remain-
ing 20 patients ≤ 11 years who did not perform CPET or
MSWT, all were aged ≤ 6 years. Whilst all patients excluded
on the basis of age happened to be aged ≤ 11 years, five chil-
dren ≤ 11 years were still able to undertake a CPET and are
therefore included in the ‘eligible’ sample of n = 138. Of the
63 eligible patients (> 12 years) who did not perform CPET,
17 refused, and a further 26 and 20 did not perform CPET for
clinical and miscellaneous reasons, respectively, with specific
reasons highlighted in Fig. 2. Of these 63, 27 performed alter-
native exercise tests: MSWT = 24 (767 ± 341 m, 240–
1410 m); 6MWT= 3 (413 ± 214 m, 279–660 m). The remain-
ing 36 patients did not perform any exercise test (clinical = 12,
refusal = 10, miscellaneous = 14; Fig. 1).
Statistically significant associations between uptake of
CPET and FEV1 category were identified (p < 0.01). A sig-
nificant logistic regression (p = 0.026) identified that individ-
uals who were eligible for CPET (i.e. no patients ≤ 11 years)
with < 40%predicted were 85.7% less likely to perform CPET
than those with FEV1 ≥ 70%predicted (p = 0.08, β = 0.143,
95% CI = 0.034–0.596). No significant associations were
found between sex and uptake of CPET (p = 0.34), nor
was sex a significant predictor of performing CPET (p =
0.26). Categories of BMI approached significance with
Table 1 Characteristics of participants analysed for study
All patients (n = 179) Eligible patients (n = 138) CPETs (n = 75) No CPET (n = 63)
Full gas (n = 62) Non-gas (n = 13)
M/F 92/87 74/64 38/24 5/8 49/55
Age (years) 22.6 (± 15.0) 27.9 (± 13.1) 26.1 (± 12.0) 22.2 (± 7.5) 20.4 (± 17.0)
FEV1 (%predicted) 74.5 (± 25.0) 72.0 (± 25.0) 75.9 (± 23.9) 79.3 (± 21.2) 72.6 (± 26.5)
BMI (kg m−2) 22.6 (± 5.4) 23.8 (± 5.0) 23.6 (± 3.6) 22.7 (± 3.4) 21.8 (± 6.6)
V̇O2max (mL kg
−1 min−1)* - - 28.85 (± 7.49) n/a n/a
All values are presented as mean (± standard deviation). CPET, cardiopulmonary exercise test; M, male; F, female; FEV1, forced expiratory volume in
one second; BMI, body mass index; V̇O2max, maximal oxygen uptake. *Ratio-standard scaling sufficient in removing residual effects of body size,
therefore VO2max scaled relative to body mass
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regard to associations (p = 0.052) as more individuals who
were normal weight and overweight performed a CPET (n =
65) versus those who did not (n = 37). In contrast, more
people who were underweight or obese did not perform
CPET (n = 18) versus those who did (n = 10). With regard
to logistic regression, BMI category was not statistically
significant (p = 0.07), although this model as a whole did
approach the statistical threshold value of p = 0.05.
However, when broken down into categories, no significant
differences were reported between groups (p > 0.22).
Discussion
This single-centre review identifies multiple reasons as
to why people with CF do not perform CPET, informa-
tion that can be utilised to further integrate CPET into
routine care. Within this cohort, 42% of all patients
performed CPET as part of their annual review process,
with this value increasing to 69% when all forms of
exercise testing were considered (CPET, MSWT and
6MWT).
Fig. 1 Flow-chart for lack of
uptake of exercise testing in a
centre-wide sample of 179 people
with cystic fibrosis. 6MWT six-
minute walk test, CPET cardio-
pulmonary exercise test, MSWT
modified shuttle walk test
Fig. 2 Reasons for lack of uptake
of cardiopulmonary exercise
testing in a combined (adult and
paediatric) CF centre. CF cystic
fibrosis, CPET cardiopulmonary
exercise test, MDT multi-
disciplinary team, NTM non-
tuberculous mycobacteria
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However, 18.8% of eligible patients did not perform CPET
for clinical reasons, such as needing intravenous antibiotics,
musculoskeletal issues and obesity. These reasons were
categorised by clinical staff, and in most instances proved to
be complete contraindications to exercise (e.g. haemoptysis),
leading to tests not being offered to patients. However, not all
clinical co-complications proved to be complete contraindica-
tions to exercise testing. For example, individuals that were
listed for, and recovering from, lung transplants were still able
to perform field tests with permission from clinicians. This
shows that exercise testing still provides prognostic informa-
tion when patients present with clinical complications (e.g. in
the post-transplant setting) although CPET may only be
deemed useful for those predicted long-term survival and ac-
companying treatment plans. Furthermore, patients who pre-
sented with microbiological contraindications to performing a
CPETwith full on-line gas analysis (n = 13) were still able to
undertake CPET using a protocol from Werkman et al. [11],
whereby peak power achieved can act as a proxy for aerobic
fitness, and in adolescents with CF, predict V̇O2peak.
A further 12.3% of eligible patients refused CPET. Within
this group, a number of patients refused because of the burden
associated with travelling to the regional hospital where CPET
takes place. However, of these travel-related refusals, half in-
stead opted for MSWTat treatment centres nearer their home.
As some patients only refused CPET because of travel, and
did not refuse exercise testing itself, this suggests an accep-
tance of exercise testing, particularly when this is considered
alongside the fact only two patients refused CPET because of
a dislike of the test.
Additionally, 14.5% of eligible patients did not perform
CPET for miscellaneous reasons (i.e. those that did not align
with ‘clinical’ nor ‘refusal’ reasons). These include communi-
cation issues, whereby it was difficult to contact some pa-
tients, and some were no longer engaged with the CF team.
Communication issues [12] have been reported previously in
relation to exercise testing in cardiology, highlighting com-
mon challenges across multiple medical disciplines.
In addition, some patients were deemed too young for formal
exercise testing. In the present review, five childrenwith CFwere
actually under the age of 11, and were able to complete CPET
(and were thus included in the eligible n= 138). The remainder
of thosewhowere excluded on the basis of age happened to be ≤
11 years, andwere not necessarily excluded because theywere ≤
11 years of age. Guidelines recommend exercise testing and
prescription from 10 years of age [3], although factors such as
physical stature, and cognitive ability to understand the demands
of the test, will influence whether a child can, and should, per-
form CPET [13]. A previous observational study of CPET in
clinical practice has shown that young children (7 years) were
unable to perform the test due to poor cooperation [4], and there-
fore testing of children should be considered on a case-by-case
basis, as shown by the present review.
When predicting factors associated with performing CPET,
only FEV1 was statistically significant, whereby those with
FEV1 < 40%predicted were less likely to undertake CPET than
individuals with FEV1 ≥ 70%predicted. In the present cohort,
only 3/15 eligible patients with FEV1 < 40%predicted performed
CPET—a proportion similar to Weir et al. [4]—compared
with 47/74 patients with FEV1 ≥ 70%predicted. Reasons why
patients with FEV1 < 40%predicted did not perform CPETwere
mainly clinical (n = 7), in contrast those with FEV1 ≥ 70%-
predicted whereby miscellaneous reasons (n = 11) were predom-
inant. Consequently, this could affect clinical practice by the
occurrence of an increased number of cancelled and/or post-
poned tests in patients with lower lung function. Therefore,
clinical teams may need to be more reactive to temporary
increases in function and clinical stability in patients, so that
CPET can be performed at a time when patients are healthy
enough to provide a valid result.
Unlike FEV1, neither sex nor BMI was a predictor, al-
though the latter may be biased by use of BMI categories for
eligible patients aged 11–18 years, whereas BMI percentile
may be more suitable [14]. Equally, given that ‘obesity’ was
a reason given for patients not undertaking CPET, it is possi-
ble the range of body sizes observed (BMI in adults = 14.50–
47.50 kg m−2) has biased this result whilst retaining a normal
distribution.
Previous studies examining uptake of CPET have focused
upon acute diagnostic referrals in American cardiac clinics,
showing both employment and insurance status [12] influenced
uptake of the test. However, previous work has focused on
socio-economic factors affecting CPET, whereas the present
analysis describes logistical challenges faced in implementing
CPET for patients and staff alike. In some instances, patients
would have been approached more than once with regard to
performing the test, as the timing of first appointments may
have been unfeasible for many reasons presented here (e.g.
receiving antibiotic), but subsequent appointments may have
been feasible (e.g. once recovered from antibiotic regimen).
Therefore, the data presented in this evaluation is only related
to patients who did not undertake CPET at any time and thus
provides a useful insight into persistent logistical challenges
faced by clinical teams in implementing CPET.
The present analysis is novel as it describes patients that (a)
have a respiratory condition and (b) have chronic disease, for
whom exercise testing would be considered a routine prog-
nostic test. However, the authors acknowledge that this ser-
vice evaluation is limited to a single centre and therefore ap-
plication of findings to further CF services may be limited. For
example, the geographical challenges faced by patients under
the care of this rural CF centre (e.g. transport links/distance)
may not exist for patients associated with urban CF centres,
and the clinical reasons faced by other centres may differ if
they have a greater number of patients, or spread of severities,
under their care. Therefore, replications of such a service
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evaluation are warranted to identify common reasons for lack
of uptake of CPETand allow for effective national implemen-
tation of this valuable measure.
Empowered with the understanding of the reasons for the
lack of uptake with CPET, CF teams can strategically utilise
this information to implement and improve services. This
could include adjusting appointments to coincide with when
patients are stable and healthy, coordination of services to
ensure laboratory availability, and changing communication
strategies to ensure patients are effectively contacted and of-
fered the opportunity to undertake the test. Equally, there are a
number of clinical cases that may not exist in following years
(e.g. musculoskeletal issues, pregnancy) and therefore, uptake
may be higher should these reasons be re-evaluated. Within
this CF centre, there were no financial challenges faced, al-
though this may be a future barrier for CF teams looking to
implement CPETas a new service. Equipment availability has
been highlighted as a barrier to undertaking in previous sur-
veys [6, 15] and therefore strategies to alleviate financial pres-
sure may be considered, such as equipment sharing with other
clinical teams within hospitals (e.g. cardiology, anaesthesiol-
ogy), or between hospitals and research institutions.
In conclusion, there are numerous factors that are respon-
sible for why patients with CF do not undertake a CPET at
annual review. These include clinical co-complications, re-
fusals and miscellaneous logistical issues. Furthermore, it
has been shown that patients with a FEV1 < 40%predicted are
less likely to undertake CPET. Further research is warranted to
identify and evaluate strategies to improve uptake of CPET for
patients with CF.
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